In biomedical research and new drug development, recombinant proteins from three major model species—monkey, mouse, and dog—serve as a vital bridge from basic research to preclinical validation. Mouse recombinant proteins, due to their high compatibility with experimental models, are widely used in studies of immune mechanisms, in vivo pharmacological evaluation, and target validation. Monkey-derived proteins […]
In recent years, nanobodies (single-domain antibodies, VHHs) have rapidly emerged as a hot research direction in antibody and biologics development, thanks to their unique structure and biological properties. Derived from camelids, these single-domain antibodies feature a small size, high stability, and easy engineering capabilities, making them ideal for applications in drug discovery, diagnostics, imaging, and immunotherapy.
Membrane proteins are molecules that are critically important for life, undertaking key functions such as signal transduction, material transport, and cell recognition. With the deepening of drug development and structural biology research, membrane proteins have become central targets for new drug discovery and mechanistic studies. However, due to their structural complexity and poor stability, their […]
Explore how recombinant proteins derived from human, mouse, monkey, and dog enable more accurate antigen selection, cross-species validation, and improved antibody discovery. Learn why multi-species antigens are essential for screening, affinity evaluation, and translational drug development.
In October 2025, the global biopharmaceutical sector remained highly active, with innovation-driven collaborations and mergers & acquisitions continuing to heat up. Major deals were struck across diverse areas—including antibody drugs, ADCs, RNA therapeutics, AI-driven drug discovery, autoimmune diseases, gene editing, drug delivery, and neurological disorders—reflecting sustained investor and industry confidence in the biopharma landscape. The […]
The SAPA-China 2025 Pharmaceutical Industry Conference will be grandly held from October 31 to November 1, 2025, at the Shishan International Conference Center in Suzhou. Under the theme “Building an Innovative Ecosystem, Opening a New Era in Pharmaceuticals,” the conference will feature one main forum and 45 parallel sub-forums, bringing together nearly 400 top leaders […]
Membrane proteins are key target families in drug discovery, including GPCRs, Claudins (CLDN), Tetraspanins, and transporters, which are involved in signal transduction and substance transport. However, their high hydrophobicity and complex structures often make them unstable in traditional systems.The Nanodisc technology encapsulates membrane proteins within a synthetic lipid bilayer, mimicking the natural membrane environment. This […]
On January 10, Harbour BioMed and Kelun-Biotech out-licensed the overseas rights of their jointly developed TSLP antibody HBM9378/SKB378 to Windward Bio. The deal reached a total value of up to USD 970 million. HBM9378/SKB378 is a fully human anti-TSLP monoclonal antibody co-developed by Harbour BioMed and Kelun-Biotech, designed to regulate immune responses by inhibiting the thymic […]
Weight loss isn’t just about “eating less and exercising more“; it’s also about the molecular dynamics behind it. While GLP-1 drugs have been a global hit over the past few years, the development of weight loss drugs extends far beyond this one. New metabolic targets are constantly being discovered, and research and clinical progress are […]
The 2025 World Lung Cancer Conference (WCLC) will be held by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain, from September 6th to 9th, 2025. As one of the most influential events in the global oncology community, WCLC provides a platform for academic exchange on the latest research findings and […]